BR112015022290A2 - derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120 - Google Patents

derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120

Info

Publication number
BR112015022290A2
BR112015022290A2 BR112015022290A BR112015022290A BR112015022290A2 BR 112015022290 A2 BR112015022290 A2 BR 112015022290A2 BR 112015022290 A BR112015022290 A BR 112015022290A BR 112015022290 A BR112015022290 A BR 112015022290A BR 112015022290 A2 BR112015022290 A2 BR 112015022290A2
Authority
BR
Brazil
Prior art keywords
benzo
fused heterocyclic
gpr120
heterocyclic derivatives
agonists
Prior art date
Application number
BR112015022290A
Other languages
English (en)
Other versions
BR112015022290B1 (pt
Inventor
L Subasinghe Nalin
Sui Zhihua
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112015022290A2 publication Critical patent/BR112015022290A2/pt
Publication of BR112015022290B1 publication Critical patent/BR112015022290B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

abstract the present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by gpr120. more particularly, the compounds of the present invention are agonists of gpr120, useful in the treatment of, such as for example, type ii diabetes mellitus. tradução do resumo resumo patente de invenção "derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120". a presente invenção é direcionada a derivados heterocíclicos benzo-fundidos, às composições farmacêuticas que os contêm e seu uso no tratamento de distúrbios e condições moduladas por gpr120. mais particularmente, os compostos da presente invenção são agonistas de gpr120, úteis no tratamento, como, por exemplo, de diabetes mellitus tipo ii.
BR112015022290-0A 2013-03-14 2014-03-07 Derivados de heterocíclicos benzo-fundidos, seu uso como agonistas de gpr120 e composição farmacêutica que os compreende BR112015022290B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783118P 2013-03-14 2013-03-14
US61/783,118 2013-03-14
PCT/US2014/021790 WO2014159061A2 (en) 2013-03-14 2014-03-07 Benzo-fused heterocyclic derivatives useful as agonists of gpr120

Publications (2)

Publication Number Publication Date
BR112015022290A2 true BR112015022290A2 (pt) 2017-07-18
BR112015022290B1 BR112015022290B1 (pt) 2022-03-03

Family

ID=50439484

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122021021616-9A BR122021021616B1 (pt) 2013-03-14 2014-03-07 Derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120, seu uso, processo de preparação e composição
BR112015022290-0A BR112015022290B1 (pt) 2013-03-14 2014-03-07 Derivados de heterocíclicos benzo-fundidos, seu uso como agonistas de gpr120 e composição farmacêutica que os compreende

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122021021616-9A BR122021021616B1 (pt) 2013-03-14 2014-03-07 Derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120, seu uso, processo de preparação e composição

Country Status (19)

Country Link
US (4) US9562053B2 (pt)
EP (2) EP3421458B1 (pt)
JP (2) JP6479751B2 (pt)
KR (2) KR102422559B1 (pt)
CN (1) CN105209444B (pt)
AU (2) AU2014241397B2 (pt)
BR (2) BR122021021616B1 (pt)
CA (1) CA2905293C (pt)
DK (2) DK3421458T3 (pt)
EA (1) EA027781B1 (pt)
ES (2) ES2836053T3 (pt)
IL (2) IL240643B (pt)
MX (1) MX2015012094A (pt)
NZ (2) NZ711191A (pt)
PH (2) PH12015501941A1 (pt)
PL (2) PL3421458T3 (pt)
SG (2) SG10201709565QA (pt)
UA (2) UA123269C2 (pt)
WO (1) WO2014159061A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102422559B1 (ko) 2013-03-14 2022-07-18 얀센 파마슈티카 엔.브이. Gpr120의 작용제로서 유용한 벤조 융합된 헤테로사이클릭 유도체
US10800773B2 (en) 2016-09-12 2020-10-13 Integral Health, Inc. Monocyclic compounds useful as GPR120 modulators
CN110121343B (zh) * 2016-09-12 2023-11-03 整体健康 用作gpr120调节剂的双环化合物
CN111868035A (zh) 2018-03-15 2020-10-30 阿克萨姆股份公司 取代的吡唑ffa4/gpr120受体激动剂
CN111153841A (zh) * 2020-01-22 2020-05-15 广东工业大学 一种巯基功能化有机芳香羧酸配体及其制备方法与应用
CN111233724A (zh) * 2020-01-22 2020-06-05 广东工业大学 一种巯基功能化有机芳香羧酸配体及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
WO2004063155A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Fused heterocyclic derivatives as ppar modulators
WO2005051373A1 (ja) * 2003-11-26 2005-06-09 Takeda Pharmaceutical Company Limited 受容体機能調節剤
EP1706386A1 (en) * 2003-12-22 2006-10-04 Eli Lilly And Company Bicyclic derivatives as ppar modulators
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
AU2007292816B2 (en) 2006-09-07 2011-11-17 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
KR20090077051A (ko) 2006-09-29 2009-07-14 액테리온 파마슈티칼 리미티드 3-아자-비시클로[3.1.0]헥산 유도체
US8394841B2 (en) 2007-02-22 2013-03-12 Irm Llc Compounds and methods for modulating G protein-coupled receptors
US8318781B2 (en) 2007-04-26 2012-11-27 Japan Science And Technology Agency G-protein-conjugated receptor agonist
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
MX2011004125A (es) 2008-10-21 2011-05-19 Metabolex Inc Agonistas del receptor gpr120 de arilo y usos de los mismos.
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8362052B2 (en) * 2009-03-11 2013-01-29 Msd K.K. Isoindolin-1-one derivative
JP5234029B2 (ja) * 2009-08-05 2013-07-10 山栄化学株式会社 無洗浄活性樹脂組成物及び表面実装技術
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
JP5746334B2 (ja) * 2010-06-16 2015-07-08 シマベイ セラピューティクス， インコーポレーテッド Ｇｐｒ１２０受容体作動薬及びその使用
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
US20140256740A1 (en) 2011-07-29 2014-09-11 Tempero Pharmaceuticals, Inc. Compounds and methods
KR102422559B1 (ko) 2013-03-14 2022-07-18 얀센 파마슈티카 엔.브이. Gpr120의 작용제로서 유용한 벤조 융합된 헤테로사이클릭 유도체

Also Published As

Publication number Publication date
WO2014159061A2 (en) 2014-10-02
NZ711191A (en) 2019-05-31
CA2905293A1 (en) 2014-10-02
SG11201507240RA (en) 2015-10-29
US10730847B2 (en) 2020-08-04
AU2014241397B2 (en) 2018-05-10
BR122021021616B1 (pt) 2022-08-30
MX2015012094A (es) 2016-04-15
IL240643A0 (en) 2015-10-29
ES2836053T3 (es) 2021-06-23
EP2970157A2 (en) 2016-01-20
DK2970157T3 (en) 2018-07-16
KR20210050601A (ko) 2021-05-07
PH12015501941B1 (en) 2016-02-01
US20190152937A1 (en) 2019-05-23
BR112015022290B1 (pt) 2022-03-03
KR102249047B1 (ko) 2021-05-07
EP3421458A1 (en) 2019-01-02
IL240643B (en) 2019-06-30
EA027781B1 (ru) 2017-08-31
US11254647B2 (en) 2022-02-22
JP2016516690A (ja) 2016-06-09
KR102422559B1 (ko) 2022-07-18
WO2014159061A3 (en) 2015-01-15
PL2970157T3 (pl) 2019-02-28
US10155737B2 (en) 2018-12-18
EP3421458B1 (en) 2020-11-11
UA123269C2 (uk) 2021-03-10
ES2673921T3 (es) 2018-06-26
AU2014241397A1 (en) 2015-09-03
US20200317629A1 (en) 2020-10-08
US20140275172A1 (en) 2014-09-18
JP6479751B2 (ja) 2019-03-06
KR20150127722A (ko) 2015-11-17
EA201591734A1 (ru) 2016-03-31
PH12015501941A1 (en) 2016-02-01
AU2018214053B2 (en) 2020-03-12
US20170088531A1 (en) 2017-03-30
CN105209444A (zh) 2015-12-30
DK3421458T3 (da) 2020-12-14
JP6802302B2 (ja) 2020-12-16
PL3421458T3 (pl) 2021-04-19
US9562053B2 (en) 2017-02-07
UA117241C2 (uk) 2018-07-10
IL267196B (en) 2021-06-30
CN105209444B (zh) 2017-12-29
EP2970157B1 (en) 2018-04-25
NZ751217A (en) 2020-07-31
IL267196A (en) 2019-08-29
PH12019500467A1 (en) 2020-11-04
JP2019094341A (ja) 2019-06-20
AU2018214053A1 (en) 2018-08-23
CA2905293C (en) 2021-10-12
SG10201709565QA (en) 2017-12-28

Similar Documents

Publication Publication Date Title
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112015022290A2 (pt) derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120
BR112015022566A2 (pt) composto e composição farmacêutica
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
GT201400144A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
EA201200176A1 (ru) Производные оксазина и их применение для лечения неврологических нарушений
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
NI201500096A (es) Compuesto químicos
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
BR112015018504A2 (pt) moduladores de flap
EA201690888A1 (ru) Новые гетероциклические соединения
CL2016000026A1 (es) Nuevos derivados de azabencimidazol
UY36195A (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
EA200901389A1 (ru) Производные фталазина и изохинолина с модулирующим действием на s1p рецепторы
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
BR112018001035A2 (pt) compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
BR112016027383A8 (pt) derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos
BR112015026048A2 (pt) análogos de combretastatina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 263/56

Ipc: C07D 263/56 (2006.01), A61K 31/343 (2006.01), A61P

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/03/2014, OBSERVADAS AS CONDICOES LEGAIS.